SCHEMBL5206571

SCHEMBL5206571

CCNCC1CCC(c2nc(-c3cccc(C(F)(F)F)c3)c[nH]2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.43
CASP6 P55212 1/20 0.41
KDM1A O60341 6/20 0.40
MAOB P27338 4/20 0.40
MAOA P21397 3/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
KCNH2 Q12809 1/20 0.40
PIM1 P11309 2/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
RPS6KA3 P51812 1/20 0.39
ADORA1 P30542 1/20 0.39
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
MAPK13 O15264 1/20 0.37
MAPK9 P45984 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205247 0.87 VCP (0.45) VCPCASP6KDM1AMAOBMAOA
SCHEMBL5202973 0.85 VCP (0.45) VCPCASP6KDM1AMAOBMAOA
SCHEMBL5202721 0.84 KDM1A (0.44) VCPKDM1AMAOBMAOAMEN1
SCHEMBL5203558 0.84 VCP (0.47) VCPKDM1AMAOBMAOAMEN1
SCHEMBL5203241 0.84 KDM1A (0.46) VCPKDM1AMAOBMEN1POLB
SCHEMBL5206200 0.81 KCNH2 (0.45) VCPCASP6KDM1AMAOBMAOA
SCHEMBL5206599 0.81 GBA1 (0.48) VCPMEN1KMT2A
SCHEMBL6964170 0.80 MAPK13 (0.43) KDM1AMAOBMAOAMEN1POLB
SCHEMBL5202992 0.79 KCNH2 (0.46) VCPKDM1AMAOBMAOAMEN1
SCHEMBL5203000 0.79 KCNH2 (0.46) VCPKDM1AMAOBMAOAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R VCP 3862/4885CASP6 4029/4885KDM1A 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.